Presented at Bioprocess International Europe, Virtual Meeting
Kristin Thiele, Sartorius Stedim
Despite the demand of ‘speed to clinic’ to bring new biotherapeutics into clinical trials, the CHO cell line development (CLD) process is associated with long development timelines, heavy manual workload and large data volumes. To overcome these obstacles in CLD sectors, we developed an accelerated, efficient and robust CLD platform, combined with flexible automated technologies and high-standard digital data management solutions. By leveraging our improved Sartorius Cellca CLD 4.0 platform we reliably generate high-yielding, stable and large-scale-cell compatible cell lines within 12 weeks. This is enabled by our integrated CLD, automation, and data management approach taking us to the next level of operational excellence.